Overview of the Requirements on WFI in the EU, USA and Japan
Recommendation

16-18 June 2026
Good Engineering Practice for Pharmaceutical Companies and Suppliers
Again and again, the question arises about the limits laid down in the different GMP regulations and Pharmacopoeias and what procedures are applicable to the manufacture of water for injection (WFI). The table below gives you an overview of the current requirements on the production as well as on certain testing elements. It is remarkable to notice that only EU authorities are against the inclusion of membrane procedures for the production of WFI.
|
| USP | EP | JP |
| Production of WFI | Distillation or purification process proven to be equivalent or superior to distillation | Distillation only | Distillation or RO/UF |
| Conductivity [µS/cm at 25 °C or equivalent at other temperatures] | 1.3 | 1.3 | 1.3 |
| TOC [ppb] | ≤ 500 | ≤500 | ≤ 500 |
| Endotoxin | 0.25 EU/mL | 0.25 EU/mL | 0.25 EU/mL |
| Bacteria [cfu/100 mL] | 10 | 10 | 10 |
| Nitrates [ppm] | N/A | 0.2 | N/A |
| Ammonium [mg/L] | N/A | N/A | N/A |
Related GMP News
03.06.2026Warning Letter regarding serious Deficiencies in Equipment, Documentation and Contamination Control
03.06.2026Questions & Answers on Manual Visual Inspection (MVI)
27.05.2026GMP Deficiencies at a PET Manufacturer
23.04.2026Visual Inspection Group Developments [January through April 2026]
08.04.2026Deficiencies in Equipment Design lead to Warning Letter
01.04.2026Rouging in pharmaceutical Water and Pure Steam Systems: Causes, Effects and Control Measures


